Development and validation of RP-HPLC-fluorescence method for quantitative determination of quinidine, a probe substrate for P-glycoprotein inhibition assay using Caco-2 cell monolayer

Biomedical Chromatography

Volumn 24, Issue 6, 2010, Pages 620-625

  Patil, Anand G ^a   Reddy, Dilip ^a   D'Souza, Russell ^a   Damre, Anagha ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Caco 2; Inhibitor; P glycoprotein; Quinidine; RP HPLC fluorescence

Indexed keywords

CALIBRATION; CELLS; GLYCOPROTEINS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MONOLAYERS; PROBES;

CACO-2; CACO-2 CELLS; CELL MONOLAYERS; FLUORESCENCE METHOD; INHIBITOR; P-GLYCOPROTEIN; PERFORMANCE; QUINIDINE; REVERSE PHASIS; REVERSE-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC FLUORESCENCE;

FLUORESCENCE;

GLYCOPROTEIN P; KETOCONAZOLE; QUINIDINE; VERAPAMIL;

ACCURACY; ANALYTIC METHOD; ARTICLE; CALIBRATION; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG STRUCTURE; FLUORESCENCE; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; MONOLAYER CULTURE; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 77952753758     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1337     Document Type: Article

References (21)

1. Ayrton A and Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469-497. (Pubitemid 32826389)
2. Balayssac D, Authier N, Cayre A and Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicology Letters 2005; 156: 319-329. (Pubitemid 40342565)
3. Balimane PV, Patel K, Marino A and Chong S. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 99-105. (Pubitemid 38781010)
4. Balimane PV, Han Y and Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS Journal 2006; 8: E1-E13.
5. Döppenschmitt S, Langguth P, Regårdh CG, Andersson TB, Hilgendorf C and Spahn-langguth H. Characterization of binding properties to human P-glycoprotein: Development of a [3H]verapamil radioligand-binding assay. Journal of Pharmacology and Experimental Therapeutics 1999; 288: 348-357. (Pubitemid 29113509)
6. Drayer DE, Restivo K and Reidenberg MM. Specific determination of quinidine and (3S) 3 hydroxyquinidine in human serum by high pressure liquid chromatography. Journal of Laboratory and Clinical Medicine 1977; 90: 816-822. (Pubitemid 8216204)
7. Elsby R, Surry DD, Smith VN and Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008; 38: 1140-1164.
8. Englund G, Hallberg P, Artursson P, Michaelsson K and Melhus H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BioMed Central Medicine 2004; 2: 1-8.
9. Flanagan RJ, Taylor AA, Watson ID and Whelpton R. Fundamentals of Analytical Toxicology. Wiley: Chichester, 2008.
10. Germain C, Karen C, Sylvie L and Martin L. Simultaneous determination of diltiazem and quinidine in human plasma by liquid chromatography. Journal of Chromatography B 1995; 672: 261-269.
11. Hoyer GL, Clawson DC, Brookshier LA, Nolan PE and Marcus F.I. High-performance liquid chromatographic method for the quantitation of quinidine and selected quinidine metabolites. Journal of Chromatography B 1991; 572: 159-169.
12. m value of efflux pump substrates. Drug Metabolism and Disposition 2007; 35: 1574-1579.
13. Leroyer R, Jarreau C and Pays M. Specific determination of quinidine and metabolites in biological fluids by reversed-phase high-performance liquid chromatography. Journal of Chromatography B 1982; 228: 366-371. (Pubitemid 12078592)
14. Pershing LK, Peat MA and Finkle BS. An HPLC method for the quantitation of quinidine and its metabolites in plasma: an application to a quinidine-phenytoin drug interaction study. Journal of Analytical Toxicology 1982; 6: 153-156.
15. Rakhit A, Kunitani M, Holford NG and Riegelman S. Improved liquid-chromatographic assay of quinidine and its metabolites in biological fluids. Clinical Chemistry 1982; 28: 1505-1509. (Pubitemid 12090696)
16. Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, Sakaeda V, Okumura K, Langguth P and Yamashita S. Induction of P-glycoprotein in caco-2 cells: development of highly sensitive assay system for P-glycoprotein mediated drug transport. Drug Metabolism and Pharmacokinetics 2006; 21: 414-423.
17. Smalley J, Kadiyala P, Xin B, Balimane P and Olah T. Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bidirectional assay samples. Journal of Chromatography B 2006; 830: 270-277. (Pubitemid 43075462)
18. Tamai G, Yoshida H, Imai H, Takashina T, Kotoo K, Fuwa T, Tsuchioka Y, Matsuura H and Kajiyama G. Isolation of new quinidine metabolites and simultaneous determination of quinidine and its metabolites in blood and urine by direct injection HPLC analysis. Chromatographia 1985; 20: 671-676.
19. Theodor WG, Peter EC, Robert AU, Daniel LC and Sidney R. Determination of quinidine and its major metabolites by high-performance liquid chromatography. Journal of Chromatography B 1979; 162: 59-70. (Pubitemid 9065229)
20. Venkatesh G, Ramanathan S, Mansor SM, Nair NK, Sattar MA, Croft SL, Navaratnam VA. Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 1546-1551. (Pubitemid 46282389)
21. US FDA. Guidance for Industry. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, September 2006.